CI & Patent News: 08/02/2011

1) Salix licenses RELISTOR from Progenics Pharmaceuticals (Press release); RELISTOR® (methylnaltrexone bromide) is opioid antagonist, indicated for treatment of opioid-induced constipation. “The methylnaltrexone license includes intellectual property from the University of Chicago, Progenics Pharmaceuticals, and Wyeth Pharmaceuticals, including patents and applications with expiration dates that will range from 2017 through 2031

2) Gilead Sciences Announces Notification of ANDA Filing for Tamiflu (oseltamivir phosphate) (Businesswire). “In the Notice Letter, Natco alleges that a patent associated with Tamiflu – U.S. Patent Number 5,763,483 – owned by Gilead Sciences is invalid, unenforceable and/or will not be infringed by Natco’s manufacture, use or sale of the product described in its ANDA submission

3) Valeant Pharmaceuticals to Acquire U.S. and Canadian Rights to Zovirax (Aciclovir) from GlaxoSmithKline for $300 million (Pharmalive)

4) Glenmark achieves positive results for anti-diarrhoea molecule (ET report); “…Crofelemer is licenced to the company from US-based Napo Pharmaceuticals. In November 2010, Glenmark along with Napo and Salix Pharmaceuticals, had announced the successful completion of phase III trials with Crofelemer for the treatment of diarrhoea inpatients with HIV in the US…

5) FDA Approves Makena (hydroxyprogesterone caproate injection), the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth (Yahoo finance)

About Guna

Interested to learn things around me
This entry was posted in Daily interesting IP news. Bookmark the permalink.

1 Response to CI & Patent News: 08/02/2011

  1. Pingback: World Spinner

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s